(Q35750986)

English

Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study

scientific article published on April 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 August 2017

Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study (English)

1 reference

Europe PubMed Central

10 August 2017

8

object named as

Stefan Faderl

1 reference

Europe PubMed Central

10 August 2017

7

object named as

Zeev Estrov

1 reference

Europe PubMed Central

10 August 2017

Srdan Verstovsek

6

object named as

Srdan Verstovsek

1 reference

Europe PubMed Central

10 August 2017

Jorge Eduardo Cortes

9

object named as

Jorge Cortes

1 reference

Europe PubMed Central

10 August 2017

Frederick R. Appelbaum

14

object named as

Frederick R Appelbaum

1 reference

Europe PubMed Central

10 August 2017

13

object named as

Elihu Estey

1 reference

Europe PubMed Central

10 August 2017

Steven M Kornblau

1

object named as

Steven M Kornblau

1 reference

Europe PubMed Central

10 August 2017

Derek L Stirewalt

3

object named as

Derek Stirewalt

1 reference

Europe PubMed Central

10 August 2017

author name string

Deborah E Banker

2

1 reference

Europe PubMed Central

10 August 2017

Danny Shen

4

1 reference

Europe PubMed Central

10 August 2017

Elizabeth Lemker

5

1 reference

Europe PubMed Central

10 August 2017

Miloslav Beran

10

1 reference

Europe PubMed Central

10 August 2017

C Ellen Jackson

11

1 reference

Europe PubMed Central

10 August 2017

Wenjing Chen

12

1 reference

Europe PubMed Central

10 August 2017

language of work or name

0 references

publication date

1 April 2007

1 reference

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

10 August 2017

109

1 reference

Europe PubMed Central

10 August 2017

7

1 reference

Europe PubMed Central

10 August 2017

2999-3006

1 reference

Europe PubMed Central

10 August 2017

Statins and cancer prevention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1852228

12 July 2018

Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1852228

12 July 2018

A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1852228

12 July 2018

Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1852228

12 July 2018

A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1852228

12 July 2018

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1852228

12 July 2018

Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1852228

12 July 2018

Regulation of the mevalonate pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1852228

12 July 2018

Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1852228

12 July 2018

Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1852228

25 September 2018

Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1852228

25 September 2018

Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1852228

25 September 2018

Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1852228

25 September 2018

Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1852228

25 September 2018

A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1852228

25 September 2018

Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1852228

25 September 2018

Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1852228

15 November 2018

Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17158228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2006-08-044446

1 reference

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35750986&oldid=1858461857"